Tara Roa, PA
Physician Assistant · Hays, KSNPI 1043286933
Payments from drug & device makers
Across 115 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$203
- Amgen$164
- Dexcom, Inc.$156
- Novo Nordisk$146
- Boehringer Ingelheim$139
- Pfizer$133
- plus $992 from 22 others
What the payments were for
- Food & beverage$1,933100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $203 |
| Amgen | 10 | $164 |
| Dexcom, Inc. | 8 | $156 |
| Novo Nordisk | 9 | $146 |
| Boehringer Ingelheim | 9 | $139 |
| Pfizer | 9 | $133 |
| Sunovion Pharmaceuticals Inc. | 9 | $101 |
| Mylan Specialty L.p. | 6 | $98 |
| AbbVie | 4 | $82 |
| Vivus LLC | 1 | $79 |
| Medtronic | 4 | $75 |
| Bayer | 5 | $74 |
| Novartis | 4 | $71 |
| Cequr Corporation | 2 | $51 |
| Insulet Corporation | 3 | $48 |
| GSK | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $32 |
| Johnson & Johnson | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $20 |
| Merck | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
How this compares
$1,933 in reported general payments places this provider in the 80th percentile of 1,016 physician assistant providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 174 | $183,677 |
| OzempicSemaglutide | 181 | $172,558 |
| Tresiba Flextouch U-200Insulin Degludec | 136 | $146,804 |
| JardianceEmpagliflozin | 160 | $137,985 |
| EliquisApixaban | 122 | $82,793 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 66 | $77,177 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $58,951 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $29,922 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $29,123 |
| Novolog FlexpenInsulin Aspart | 118 | $27,527 |
| TrulicityDulaglutide | 28 | $25,258 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $23,296 |
| FiaspInsulin Aspart (Niacinamide) | 19 | $21,397 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $20,601 |
| RybelsusSemaglutide | 11 | $16,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Tresiba, Novolog | $146 | $230,557268 claims |
| Lilly USA, LLCMounjaro, Trulicity | $203 | $208,935202 claims |
| Boehringer IngelheimJardiance | $139 | $137,985160 claims |
| PfizerEliquis | $133 | $82,793122 claims |
| GSKTrelegy Ellipta | $47 | $16,13928 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $34 | $14,09529 claims |
| AbbVieLinzess | $82 | $13,77319 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $13,38523 claims |
| AstraZenecaFarxiga | $14 | $11,69718 claims |
| MerckJanuvia | $19 | $9,33214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in Hays
- Lori WilliamsHays$9K
- Sierra FergusonWichita$25K
- Dylan TimmermannTopeka$19K
- Heather HowellKansas City$16K
- Amy BrettmanShawnee$14K
- Ashton YoungersWichita$14K
- Anthony GunawanLakin$13K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
- Melissa WilkesFort Riley$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.